Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis Maillet

Showing results (1-10 of 70) with videos related to

Pageof 7
Sort By:
Bulletin Du Cancer|June 27, 2022
Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patientDelphine Borchiellini, Denis Maillet
Transplant Immunology|August 7, 2024
Major drug-drug interaction between sirolimus and apalutamide in a liver transplant recipientJérôme Dumortier, Marc Colombel, Denis Maillet
Bulletin Du Cancer|May 27, 2019
[New drugs toxicities: A new fight]Jacques-Olivier Bay, Gilles L'Allemain, Denis Maillet
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2013
Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangementDenis Maillet, Isabelle Martel-Lafay, Dominique Arpin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2015
Aggregated adverse-events outcomes in oncology phase III reports: A systematic reviewDenis Maillet, Hui K Gan, Jean-Yves Blay, et al.
Bulletin Du Cancer|December 28, 2019
[Thyroid dysfunctions secondary to cancer immunotherapy]Christine Cugnet Anceau, Juliette Abeillon, Denis Maillet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic reviewJulien Péron, Denis Maillet, Hui K Gan, et al.
Biomedicines|November 11, 2022
Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus NivolumabFélix Pham, Samy Belkaid, Denis Maillet, et al.
Clinical Genitourinary Cancer|December 28, 2018
Pure Seminoma and Concurrent Aggressive Lymphoma: Case Report of a Patient With Persistent Müllerian Duct SyndromeElise Bonnet, Sophie Tartas, Anne Lazareth, et al.
Tumori|May 15, 2024
Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?Pierre Cornillon, Wafa Bouleftour, Thomas Reynaud, et al.
Pageof 7

Showing results (1-10 of 70) with videos related to

Sort By:
Pageof 7
Bulletin Du Cancer|June 27, 2022
Clinical activity of immunotherapy-based combination first-line therapies for metastatic renal cell carcinoma: the right treatment for the right patientDelphine Borchiellini, Denis Maillet
Transplant Immunology|August 7, 2024
Major drug-drug interaction between sirolimus and apalutamide in a liver transplant recipientJérôme Dumortier, Marc Colombel, Denis Maillet
Bulletin Du Cancer|May 27, 2019
[New drugs toxicities: A new fight]Jacques-Olivier Bay, Gilles L'Allemain, Denis Maillet
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 15, 2013
Ineffectiveness of crizotinib on brain metastases in two cases of lung adenocarcinoma with EML4-ALK rearrangementDenis Maillet, Isabelle Martel-Lafay, Dominique Arpin, et al.
European Journal of Cancer (Oxford, England : 1990)|December 3, 2015
Aggregated adverse-events outcomes in oncology phase III reports: A systematic reviewDenis Maillet, Hui K Gan, Jean-Yves Blay, et al.
Bulletin Du Cancer|December 28, 2019
[Thyroid dysfunctions secondary to cancer immunotherapy]Christine Cugnet Anceau, Juliette Abeillon, Denis Maillet, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 25, 2013
Adherence to CONSORT adverse event reporting guidelines in randomized clinical trials evaluating systemic cancer therapy: a systematic reviewJulien Péron, Denis Maillet, Hui K Gan, et al.
Biomedicines|November 11, 2022
Impact of Bone Metastases on Patients with Renal Cell Carcinoma or Melanoma Treated with Combotherapy Ipilimumab Plus NivolumabFélix Pham, Samy Belkaid, Denis Maillet, et al.
Clinical Genitourinary Cancer|December 28, 2018
Pure Seminoma and Concurrent Aggressive Lymphoma: Case Report of a Patient With Persistent Müllerian Duct SyndromeElise Bonnet, Sophie Tartas, Anne Lazareth, et al.
Tumori|May 15, 2024
Immunogenicity of radiotherapy on bone metastases from prostate adenocarcinoma: What is the future for the combination with radiotherapy/immunotherapy?Pierre Cornillon, Wafa Bouleftour, Thomas Reynaud, et al.
Pageof 7